Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
Conditions
Interventions
Placebo
Enicepatide
Locations
28
United States
Pinnacle Research Group
Anniston, Alabama, United States
Arizona Clinical Trials
Tucson, Arizona, United States
Artemis Institute for Clinical Research, LLC
San Diego, California, United States
Elevate Clinical Research
Gurnee, Illinois, United States
Monroe Biomedical Research
Louisville, Kentucky, United States
International Diabetes Center At Park Nicollet
Minneapolis, Minnesota, United States
Start Date
March 16, 2026
Primary Completion Date
July 24, 2028
Completion Date
August 28, 2028
Last Updated
April 24, 2026
NCT07255209
NCT07128888
NCT06862791
NCT07081958
NCT06867718
NCT05996848
Reference Study ID Number: WC45725 https://forpatients.roche.com/
CONTACT
888-662-6728 (U.S. Only)global-roche-genentech-trials@gene.comLead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions